Cuervo, GuillermoCamoez, MarianaShaw, EvelynAngeles Dominguez, MariaGasch, OriolPadilla, BelenPintado, VicenteAlmirante, BenitoMolina, JoseLopez-Medrano, FranciscoRuiz de Gopegui-Bordes, EnriqueMartinez, Jose ABereciartua, ElenaRodriguez-Lopez, FernandoFernandez-Mazarrasa, CarlosAngel Goenaga, MiguelBenito, NatividadRodriguez-Bano, JesusEspejo, ElenaPujol, MiquelREIPI GEIH Study Grp2024-07-042024-07-042015-10-30Cuervo G, Camoez M, Shaw E, Dominguez MA, Gasch O, Padilla B, et al. Methicillin-resistant Staphylococcus aureus (MRSA) catheter-related bacteraemia in haemodialysis patients. BMC Infect Dis. 2015 Oct 30;15:484.1471-2334http://hdl.handle.net/20.500.13003/10657http://hdl.handle.net/20.500.12105/20155Background: The aim of the study was to determine clinical and microbiological differences between patients with methicillin-resistant Staphylococcus aureus (MRSA) catheter-related bacteraemia (CRB) undergoing or not undergoing haemodialysis, and to compare outcomes. Methods: Prospective multicentre study conducted at 21 Spanish hospitals of patients with MRSA bacteraemia diagnosed between June 2008 and December 2009. Patients with MRSA-CRB were selected. Data of patients on haemodialysis (HD-CRB) and those not on haemodialysis (non-HD-CRB) were compared. Results: Among 579 episodes of MRSA bacteraemia, 218 (37.7 %) were CRB. Thirty-four (15.6 %) were HD-CRB and 184 (84.4 %) non-HD-CRB. All HD-CRB patients acquired the infection at dialysis centres, while in 85.3 % of the non-HD-CRB group the infection was nosocomial (p < .001). There were no differences in age, gender or severity of bacteraemia (Pitt score); comorbidities (Charlson score >= 4) were higher in the HD-CRB group than in the non-HD-CRB group (73.5 % vs. 46.2 %, p = .003). Although there were no differences in VAN-MIC >= 1.5 mg/L according to microdilution, using the E-test a higher rate of VAN-MIC >= 1.5 mg/L was observed in HD-CRB than in non-HD-CRB patients (63.3 % vs. 44.1 %, p = .051). Vancomycin was more frequently administered in the HD-CRB group than in the non-HD-CRB group (82.3 % vs. 42.4 %, p = <. 001) and therefore the appropriate empirical therapy was significantly higher in HD-CRB group (91.2 % vs. 73.9 %, p = .029). There were no differences with regard to catheter removal (79.4 % vs. 84.2 %, p = .555, respectively). No significant differences in mortality rate were observed between both groups (Overall mortality: 11.8 % vs. 27.2 %, p = .081, respectively), but there was a trend towards a higher recurrence rate in HD-CRB group (8.8 % vs. 2.2 %, p = .076). Conclusions: In our multicentre study, ambulatory patients in chronic haemodialysis represented a significant proportion of cases of MRSA catheter-related bacteraemia. Although haemodialysis patients with MRSA catheter-related bacteraemia had significantly more comorbidities and higher proportion of strains with reduced vancomycin susceptibility than non-haemodialysis patients, overall mortality between both groups was similar.enghttp://creativecommons.org/licenses/by/4.0/BacteraemiaCatheter-relatedHaemodialysisMRSABacteremiaAgedSpainAnti-Bacterial AgentsCross InfectionHumansRenal DialysisMiddle AgedMaleProspective StudiesFemaleMethicillin-Resistant Staphylococcus aureusTreatment OutcomeVancomycinCatheter-Related InfectionsComorbidityStaphylococcal Infectionsresearch articleAttribution 4.0 International265184871548410.1186/s12879-015-1227-yBMC Infectious Diseasesopen accessResultado del TratamientoVancomicinaComorbilidadInfecciones EstafilocócicasFemeninoMasculinoDiálisis RenalStaphylococcus aureus Resistente a MeticilinaHumanosPersona de Mediana EdadEstudios ProspectivosAncianoInfección HospitalariaBacteriemiaAntibacterianosInfecciones Relacionadas con CatéteresEspaña2-s2.0-84945907463364278200001L606719322